This review focuses on current in vivo CAR-T delivery strategies, including viral vectors (such as lentiviruses, γ-retroviruses, adeno-associated viruses, and viral-like particles)...
First-pass extracted concept
lentiviral vectors
Candidate: concept label5 source documents8 linked claims
Live refresh every 5sNext refresh in 5s
Aliases
lentiviral vectors, LVs
Evidence Snippets
Lentiviral vectors (LVs) have revolutionized gene therapy by enabling stable gene integration into dividing and non-dividing cells
while lentiviral vectors support applications in oncology and immune-related disorders.
Most are derived from lentiviral vectors, which confer a series of advantages due to their superior efficiency.
Using two delivery approaches-lentiviral vectors and lipid nanoparticles (LNPs)-we generated FAP-CAR-engineered Jurkat cells as a preliminary screening model
Supporting Sources
Linked Claims
Lentiviral vectors enable stable gene integration in dividing and non-dividing cells.
Producing high-titer functional lentiviral vectors at industrial scale remains challenging because scalability, cost-efficiency, and effectiveness need improvement.
Lentiviral vectors support applications in oncology and immune-related disorders.
Since 2021, the FDA has approved seven new viral vector-based gene therapies.
Current in vivo CAR-T delivery platforms are engineered to achieve efficient, specific, and safe CAR transgene transfer.
Viral vector technologies are maturing from proof-of-concept studies toward precision platforms capable of addressing rare monogenic disorders and more prevalent complex diseases.
Most pseudotyped viruses are derived from lentiviral vectors, which offer advantages due to superior efficiency.
The study used lentiviral vectors and lipid nanoparticles to generate FAP-CAR-engineered Jurkat cells as a preliminary screening model.
Quoted textsource-backed
Using two delivery approaches-lentiviral vectors and lipid nanoparticles (LNPs)-we generated FAP-CAR-engineered Jurkat cells as a preliminary screening model